Healthcare of Ontario Pension Plan Trust Fund Buys New Position in Indivior PLC $INDV

Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Indivior PLC (NASDAQ:INDV) during the 4th quarter, HoldingsChannel reports. The institutional investor bought 2,304,545 shares of the company’s stock, valued at approximately $82,687,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Salomon & Ludwin LLC bought a new stake in shares of Indivior during the 4th quarter valued at about $30,000. Harbor Capital Advisors Inc. raised its stake in Indivior by 309.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after buying an additional 781 shares during the period. Quarry LP acquired a new position in Indivior during the 3rd quarter worth approximately $26,000. GAMMA Investing LLC raised its stake in Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after buying an additional 1,013 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Indivior during the 2nd quarter worth approximately $26,000. Institutional investors own 60.33% of the company’s stock.

Indivior Price Performance

Shares of Indivior stock opened at $38.48 on Monday. The company has a market cap of $4.69 billion, a PE ratio of 19.73 and a beta of 0.88. Indivior PLC has a 52 week low of $13.45 and a 52 week high of $41.00. The business has a 50 day moving average price of $35.44 and a 200-day moving average price of $34.31.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. The company had revenue of $317.00 million during the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%. As a group, research analysts anticipate that Indivior PLC will post 4.05 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on INDV. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Weiss Ratings downgraded Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $39.33.

Insider Activity at Indivior

In related news, CFO Ryan Preblick sold 36,000 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the sale, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at approximately $10,735,112.70. This trade represents a 11.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.